Organization: Novartis, Merck & Co

Structural Genomics Consortium funding announced

Complete funding for the second phase of the Structural Genomics Consortium has been announced, with 13 partners (including three pharmaceutical firms) providing more than $105 million. The consortium — led by Dr Aled Edwards at the Univ of Toronto with three nodes in Toronto, the Univ of Oxford and the Karolinska Institutet — is dedicated…